Literature DB >> 11177567

Supplemental guidance on testing for replication-competent retrovirus in retroviral vector-based gene therapy products and during follow-up of patients in clinical trials using retroviral vectors.

.   

Abstract

Entities:  

Mesh：

Year:  2001        PMID： 11177567     DOI： 10.1089/10430340150218440

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN： 1043-0342            Impact factor:   5.695


× No keyword cloud information.
  33 in total

1.  A safety grading scale to support dose escalation and define stopping rules for healthy subject first-entry-into-man studies: some points to consider from the French Club Phase I working group.

Authors:  Michel Sibille; Alain Patat; Henri Caplain; Yves Donazzolo
Journal:  Br J Clin Pharmacol       Date:  2010-11       Impact factor: 4.335

2.  Replication-competent lentivirus analysis of clinical grade vector products.

Authors:  Kenneth Cornetta; Jing Yao; Aparna Jasti; Sue Koop; Makhaila Douglas; David Hsu; Larry A Couture; Troy Hawkins; Lisa Duffy
Journal:  Mol Ther       Date:  2010-12-21       Impact factor: 11.454

Review 3.  Progress and challenges in viral vector manufacturing.

Authors:  Johannes C M van der Loo; J Fraser Wright
Journal:  Hum Mol Genet       Date:  2015-10-30       Impact factor: 6.150

4.  Analysis of partial recombinants in lentiviral vector preparations.

Authors:  Seraphin Kuate; Michael P Marino; Jakob Reiser
Journal:  Hum Gene Ther Methods       Date:  2014-02-14       Impact factor: 2.396

5.  Gene Transfer to HSCs: Finding the Leukemia in Murine Leukemia Viruses.

Authors:  Kenneth Cornetta
Journal:  Mol Ther       Date:  2019-05-17       Impact factor: 11.454

6.  Reducing Ex Vivo Culture Improves the Antileukemic Activity of Chimeric Antigen Receptor (CAR) T Cells.

Authors:  J Joseph Melenhorst; Michael C Milone; Saba Ghassemi; Selene Nunez-Cruz; Roddy S O'Connor; Joseph A Fraietta; Prachi R Patel; John Scholler; David M Barrett; Stefan M Lundh; Megan M Davis; Felipe Bedoya; Changfeng Zhang; John Leferovich; Simon F Lacey; Bruce L Levine; Stephan A Grupp; Carl H June
Journal:  Cancer Immunol Res       Date:  2018-07-20       Impact factor: 11.151

7.  Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy.

Authors:  Daniel Hollyman; Jolanta Stefanski; Mark Przybylowski; Shirley Bartido; Oriana Borquez-Ojeda; Clare Taylor; Raymond Yeh; Vanessa Capacio; Malgorzata Olszewska; James Hosey; Michel Sadelain; Renier J Brentjens; Isabelle Rivière
Journal:  J Immunother       Date:  2009 Feb-Mar       Impact factor: 4.456

8.  Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells.

Authors:  Ronald T Mitsuyasu; Thomas C Merigan; Andrew Carr; Jerome A Zack; Mark A Winters; Cassy Workman; Mark Bloch; Jacob Lalezari; Stephen Becker; Lorna Thornton; Bisher Akil; Homayoon Khanlou; Robert Finlayson; Robert McFarlane; Don E Smith; Roger Garsia; David Ma; Matthew Law; John M Murray; Christof von Kalle; Julie A Ely; Sharon M Patino; Alison E Knop; Philip Wong; Alison V Todd; Margaret Haughton; Caroline Fuery; Janet L Macpherson; Geoff P Symonds; Louise A Evans; Susan M Pond; David A Cooper
Journal:  Nat Med       Date:  2009-02-15       Impact factor: 53.440

9.  Phase I/II and phase II studies of targeted gene delivery in vivo: intravenous Rexin-G for chemotherapy-resistant sarcoma and osteosarcoma.

Authors:  Sant P Chawla; Victoria S Chua; Lita Fernandez; Doris Quon; Andreh Saralou; William C Blackwelder; Frederick L Hall; Erlinda M Gordon
Journal:  Mol Ther       Date:  2009-06-16       Impact factor: 11.454

10.  Advanced phase I/II studies of targeted gene delivery in vivo: intravenous Rexin-G for gemcitabine-resistant metastatic pancreatic cancer.

Authors:  Sant P Chawla; Victoria S Chua; Lita Fernandez; Dorris Quon; William C Blackwelder; Erlinda M Gordon; Frederick L Hall
Journal:  Mol Ther       Date:  2009-10-13       Impact factor: 11.454
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.